Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYBN Cybin	$8.32 -1.7%	$7.85	$4.81 ▼ $13.88	$194.78M	0.69	291,101 shs	436,714 shs
IMAB I-Mab	$2.10 -2.8%	$1.90	$0.60 ▼ $3.08	$171.49M	1.4	391,927 shs	151,326 shs
PLUR Pluri	$4.95 -8.5%	$4.85	$3.33 ▼ $7.13	$40.93M	0.79	20,870 shs	6,705 shs
VYGR Voyager Therapeutics	$3.24 +0.6%	$3.19	$2.65 ▼ $9.55	$179.29M	0.85	491,338 shs	465,578 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYBN Cybin	0.00%	+8.90%	+5.32%	+13.20%	+2,154.74%
IMAB I-Mab	0.00%	-1.41%	-9.87%	+147.06%	+38.16%
PLUR Pluri	0.00%	-6.78%	+14.85%	+26.11%	-13.61%
VYGR Voyager Therapeutics	0.00%	-7.16%	+6.58%	+2.53%	-62.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYBN Cybin	3.0946 of 5 stars	3.6	0.0	0.0	3.8	0.8	1.3
IMAB I-Mab	2.9078 of 5 stars	3.7	3.0	0.0	2.3	1.7	0.6
PLUR Pluri	2.9527 of 5 stars	3.5	5.0	0.0	0.6	3.3	0.0
VYGR Voyager Therapeutics	3.8806 of 5 stars	3.6	2.0	4.6	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYBN Cybin	3.25	Buy	$85.00	921.63% Upside
IMAB I-Mab	3.33	Buy	$6.00	185.71% Upside
PLUR Pluri	3.00	Buy	$12.00	142.42% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	313.27% Upside

Current Analyst Ratings Breakdown

Latest PLUR, CYBN, VYGR, and IMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/2/2025	PLUR Pluri	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
6/2/2025	PLUR Pluri	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/13/2025	CYBN Cybin	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
IMAB I-Mab	$3.89M	44.08	N/A	N/A	$2.47 per share	0.85
PLUR Pluri	$330K	118.05	N/A	N/A	$1.00 per share	4.95
VYGR Voyager Therapeutics	$80M	2.24	N/A	N/A	$5.49 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYBN Cybin	-$57.88M	-$3.88	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)
PLUR Pluri	-$20.89M	-$5.53	N/A	∞	N/A	-2,563.29%	-4,191.91%	-85.40%	9/16/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)

Latest PLUR, CYBN, VYGR, and IMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	N/A	N/A	N/A	$9.50 million	N/A
5/13/2025	Q3 2025	PLUR Pluri	N/A	-$0.94	N/A	-$0.94	N/A	$0.43 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYBN Cybin	N/A	24.24	24.24
IMAB I-Mab	N/A	22.35	22.35
PLUR Pluri	51.65	4.81	4.81
VYGR Voyager Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYBN Cybin	17.94%
IMAB I-Mab	38.38%
PLUR Pluri	16.59%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
CYBN Cybin	15.00%
IMAB I-Mab	22.10%
PLUR Pluri	25.93%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYBN Cybin	50	23.02 million	17.96 million	Not Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
PLUR Pluri	150	7.87 million	5.83 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	51.80 million	Optionable

PLUR, CYBN, VYGR, and IMAB Headlines

Recent News About These Companies

Head to Head Survey: Acumen Pharmaceuticals (NASDAQ:ABOS) & Voyager Therapeutics (NASDAQ:VYGR)

July 20 at 2:09 AM | americanbankingnews.com

Mascarene Partners Acquires Voyager Trucking

July 18 at 4:31 PM | finance.yahoo.com

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18 at 4:31 PM | bioworld.comB

Mascarene buys US waste services company Voyager Trucking

July 18 at 4:31 PM | realassets.ipe.comR

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18 at 4:31 PM | pehub.com

Looking Beyond Voyager 1 And 2

July 17 at 9:27 AM | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

Uranus Heat Readings Contradict 40-Year-Old Voyager 2 Results

July 16, 2025 | msn.com

Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16, 2025 | finanznachrichten.de

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16, 2025 | globenewswire.com

Moon + Bird acquires Alastair Chisholm's book about NASA’s Voyager 1

July 15, 2025 | thebookseller.comT

Embark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and More

July 14, 2025 | prestigeonline.comP

Voyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star Trek

July 14, 2025 | fandomwire.comF

UK awards AirTanker network node upgrade for Voyager

July 11, 2025 | janes.comJ

Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology

July 10, 2025 | msn.com

RNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'

July 7, 2025 | itv.comI

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager

July 6, 2025 | cruiseindustrynews.comC

With Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-Wallets

July 5, 2025 | travelmole.comT

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

July 5, 2025 | marketbeat.com

Ant International launches Alipay+ Voyager, an AI-powered travel assistant inside e-wallets

July 3, 2025 | walastech.comW

VYGR Voyager Therapeutics, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR, CYBN, VYGR, and IMAB Company Descriptions

Cybin NYSE:CYBN

$8.32 -0.14 (-1.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.36 +0.04 (+0.49%)

As of 07/18/2025 08:00 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

I-Mab NASDAQ:IMAB

$2.10 -0.06 (-2.78%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.10 +0.00 (+0.24%)

As of 07/18/2025 07:17 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Pluri NASDAQ:PLUR

$4.95 -0.46 (-8.50%)

Closing price 07/18/2025 03:34 PM Eastern

Extended Trading

$4.66 -0.29 (-5.86%)

As of 07/18/2025 07:38 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Voyager Therapeutics NASDAQ:VYGR

$3.24 +0.02 (+0.62%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.23 -0.01 (-0.31%)

As of 07/18/2025 07:37 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time